Structure of Fasiglifam
CAS No.: 1000413-72-8
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Fasiglifam (TAK-875) is a potent, selective, and orally bioavailable GPR40 agonist with an EC50 of 72 nM.
Synonyms: Tak-875
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 1000413-72-8 |
Formula : | C29H32O7S |
M.W : | 524.63 |
SMILES Code : | O=C(O)C[C@@H]1COC2=CC(OCC3=CC(C4=C(C)C=C(OCCCS(=O)(C)=O)C=C4C)=CC=C3)=CC=C12 |
Synonyms : |
Tak-875
|
MDL No. : | MFCD18251445 |
InChI Key : | BZCALJIHZVNMGJ-HSZRJFAPSA-N |
Pubchem ID : | 24857286 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
In Vitro:
Cell Line
|
Concentration | Treated Time | Description | References |
HEK293 cells | 10 µM | 2 hours | Evaluate the binding ability of Fasiglifam to GPR40 receptor | PMC5917010 |
CHO-GPR40 cells | 5 μM | 1 hour | To determine agonistic activity of compounds against FFA1 receptor, results showed compounds 4b and 4c activated 80% and 61% receptor activity at 5 μM concentration, respectively | PMC6021034 |
Mouse colonic mucosal cells | 300 nM | 10–15 minutes | To compare the pharmacology of FFA1 and FFA4 agonists, finding selective agonists more potent than GW9508 | PMC5715575 |
Human airway smooth muscle (HASM) cells | 10 µM | 30 min | TAK875 significantly attenuated histamine-induced MLC phosphorylation and cortical tension development, while GW9508 showed little effect. | PMC7708129 |
RIN-m5f cells | 30 or 150 mg/mL | 48 hours | To evaluate the effect of YD on insulin secretion in high-glucose and high-fat injured RIN-m5f cells. Results showed that high concentration YD (150 mg/mL) significantly increased glucose-stimulated insulin secretion (GSIS) levels, similar to the TAK-875 group. | PMC10043368 |
Human liver organoids (HLOs) | 3, 10, 30 μM | 7 days | To evaluate oxidative stress and immune responses induced by TAK-875. Results showed that TAK-875 treatment led to increased ROS formation and significant release of inflammatory cytokines MCP-1 and IL-6. | PMC9981852 |
In Vivo:
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
Mice | GPR40 knockout mice | Oral | 10 mg/kg | Single dose | Evaluate the effect of Fasiglifam on blood glucose and insulin levels | PMC5917010 |
SD rats | Oral glucose tolerance test | Oral | 10 mg/kg | Single dose | Evaluate the effect of HWL-088 on glucose tolerance in rats | PMC7174891 |
ZDF (fa/fa) rats | Type 2 diabetic rat model | Gavage | 10 mg/kg/day | Once daily for 10 weeks | To evaluate the effect of TAK-875 on blood glucose and insulin secretion in type 2 diabetic rats. Results showed that TAK-875 significantly reduced fasting blood glucose (FBG) and the area under the curve (AUC) of OGTT, and increased the AUC of insulin release test (IRT) and glucose-stimulated insulin secretion (GSIS). | PMC10043368 |
Mice | Diabetes model | Intraperitoneal injection | 27 mg/kg | Single dose | To evaluate the effect of FFA1 agonist on blood glucose control, finding it improved glucose tolerance | PMC5715575 |
Mice | Gpr40 knockout and wild-type mice | Oral | 30 mg/kg | Single dose, evaluated after 30 minutes | To assess the effect of GPR40 agonists on plasma GLP-1 and GIP levels. Results showed that Gq+Gs agonists like AM-1638 and AM-5262 significantly increased plasma GLP-1 and GIP levels. | PMC4314522 |
Rats | Type 1 diabetes model rats | Oral | 5 and 10 mg/kg | Immediately before glucose load | TAK-875 (a GPR40 agonist) did not decrease postprandial blood glucose levels up to 30 min after glucose load. | PMC10424117 |
Collaborative Cross mice | Collaborative Cross mice | Oral gavage | 600 mg/kg | Single dose | To evaluate the mechanisms of TAK-875-induced liver injury and genetic risk factors in Collaborative Cross mice. Results showed that a single high dose of TAK-875 did not cause overt liver injury, but gene expression profiling revealed transcriptional changes associated with immune response, bile acid homeostasis, oxidative stress, and mitochondrial dysfunction. | PMC8936092 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT01433393 | Diabetes Mellitus | Phase 3 | Completed | - | Japan ... More >> Kisarazu-shi, Chiba, Japan Matsuyama-shi, Ehime, Japan Fukuoka-shi Nishi-ku, Fukuoka, Japan Kasuga-shi, Fukuoka, Japan Naka-shi, Ibaragi, Japan Tsuchiura-shi, Ibaragi, Japan Takamatsu-shi, Kagawa, Japan Kyoto-shi Fushimi-ku, Kyoto, Japan Nagasaki-shi, Nagasaki, Japan Kashihara-shi, Nara, Japan Kashiwara-shi, Osaka, Japan Osaka-shi Tsurumi-ku, Osaka, Japan Sakai-shi Nishi-ku, Osaka, Japan Shimotsuke-shi, Tochigi, Japan Chiyoda-ku, Tokyo, Japan Itabashi-ku, Tokyo, Japan Ota-ku, Tokyo, Japan Shinjuku-ku, Tokyo, Japan Toshima-ku, Tokyo, Japan Less << |
NCT01585792 | Diabetic Patients | Phase 3 | Completed | - | Japan ... More >> Fukuoka-shi, Fukuoka, Japan Sumida-ku, Tokyo, Japan Less << |
NCT01007097 | Diabetes Mellitus, Type 2 | Phase 2 | Completed | - | - |
NCT01433406 | Diabetes Mellitus | Phase 3 | Completed | - | - |
NCT01414920 | Diabetes Mellitus, Type 2 | Phase 2 | Completed | - | - |
NCT01433419 | Diabetes Mellitus | Phase 3 | Completed | - | Japan ... More >> Katori-shi, Chiba, Japan Niihama-shi, Ehime, Japan Chikushino-shi, Fukuoka, Japan Fukuoka-shi, Fukuoka, Japan Onga-gun, Fukuoka, Japan Yukuhashi-shi, Fukuoka, Japan Hiroshima-shi, Hiroshima, Japan Chitose-shi, Hokkaido, Japan Sapporo-shi, Hokkaido, Japan Koga-shi, Ibaragi, Japan Ushiku-shi, Ibaragi, Japan Chigasaki-shi, Kanagawa, Japan Kamakura-shi, Kanagawa, Japan Minamata-shi, Kumamoto, Japan Yatsushiro-shi, Kumamoto, Japan Sasebo-shi, Nagasaki, Japan Kashihara-shi, Nara, Japan Okinawa-shi, Okinawa, Japan Izumi-shi, Osaka, Japan Suita-shi, Osaka, Japan Fujimi-shi, Saitama, Japan Shimotsuga-gun, Tochigi, Japan Komatsushima-shi, Tokushima, Japan Bunkyo-ku, Tokyo, Japan Chiyoda-ku, Tokyo, Japan Mitaka-shi, Tokyo, Japan Shibuya-ku, Tokyo, Japan Shinjuku-ku, Tokyo, Japan Toshima-ku, Tokyo, Japan Shunan-shi, Yamaguchi, Japan Ube-shi, Yamaguchi, Japan Less << |
NCT01456195 | Diabetes Mellitus, Type 2 | Phase 3 | Completed | - | - |
NCT01549964 | Glycemic Control | Phase 3 | Terminated(Due to concerns abo... More >>ut potential liver safety (See Detailed Description)) Less << | - | - |
NCT01834274 | Diabetes Mellitus, Type 2 | Phase 3 | Terminated(Due to potential co... More >>ncerns about liver safety (See Detailed Description)) Less << | - | - |
NCT01834274 | - | Terminated(Due to potential co... More >>ncerns about liver safety (See Detailed Description)) Less << | - | - | |
NCT01982253 | Type 2 Diabetes Mellitus | Phase 2 | Terminated(Due to potential co... More >>ncerns about liver safety (See Detailed Description)) Less << | - | - |
NCT01982253 | - | Terminated(Due to potential co... More >>ncerns about liver safety (See Detailed Description)) Less << | - | - | |
NCT01481116 | - | Terminated(Due to potential co... More >>ncerns about liver safety (See Detailed Description)) Less << | - | - | |
NCT01549964 | - | Terminated(Due to concerns abo... More >>ut potential liver safety (See Detailed Description)) Less << | - | - | |
NCT02015780 | Type 2 Diabetes Mellitus ... More >> Chronic Kidney Disease Less << | Phase 3 | Withdrawn(Due to potential con... More >>cerns about liver safety (See Detailed Description)) Less << | January 2016 | - |
NCT01481116 | Diabetes Mellitus, Type 2 | Phase 3 | Terminated(Due to potential co... More >>ncerns about liver safety (See Detailed Description)) Less << | - | - |
NCT01456195 | - | Completed | - | - | |
NCT01829464 | Diabetes | Phase 3 | Terminated(Due to potential co... More >>ncerns about liver safety (See Detailed Description)) Less << | - | - |
NCT01829477 | Diabetes Mellitus, Type 2 | Phase 3 | Terminated(Due to potential co... More >>ncerns about liver safety (See Detailed Description)) Less << | - | - |
NCT00949091 | Diabetes Mellitus, Type 2 | Phase 1 | Completed | - | - |
NCT01496443 | Pharmacokinetics | Phase 1 | Completed | - | United States, Texas ... More >> San Antonio, Texas, United States Less << |
NCT01829477 | - | Terminated(Due to potential co... More >>ncerns about liver safety (See Detailed Description)) Less << | - | - | |
NCT01647542 | Type 2 Diabetes Mellitus | Phase 3 | Terminated(Due to potential co... More >>ncerns about liver safety (See Detailed Description)) Less << | - | - |
NCT01647542 | - | Terminated(Due to potential co... More >>ncerns about liver safety (See Detailed Description)) Less << | - | - | |
NCT01609582 | - | Terminated(Due to potential co... More >>ncerns about liver safety (See Detailed Description)) Less << | - | - | |
NCT01829464 | - | Terminated(Due to potential co... More >>ncerns about liver safety (See Detailed Description)) Less << | - | - | |
NCT01609582 | Type 2 Diabetes ... More >> Cardiovascular Disease Less << | Phase 3 | Terminated(Due to potential co... More >>ncerns about liver safety (See Detailed Description)) Less << | - | - |
Tags: Fasiglifam | TAK-875 | TAK875 | TAK 875 | Free Fatty Acid Receptor | FFAR | GPR40 agonist | glucose-dependent insulin secretion | 1000413-72-8
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL